-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Features and Innovations of GVHD Experimental Platforms
Author:
InnoModels
Release time:
2024-04-23
GVHD (graft-versus-host disease) has always been a complex and important topic in the field of biomedical research. With its unique features and cutting-edge technology, the GVHD experimental platform of InnoModels Biotechnology is gradually becoming a research plateau in this field. In this article, we would like to introduce several major features of the GVHD experimental platform, in order to provide new ideas and methods for the majority of researchers.
1、Highly customizable: personalized gene modification solutions
The GVHD experimental platform focuses on the individual differences of patients and provides personalized gene modification solutions according to the specific conditions of different patients. This highly customized service model ensures the accuracy and reliability of the experimental results and provides more relevant clinical data for GVHD research.
2、Efficiency: one-stop service model
In order to improve research efficiency, the GVHD experimental platform of InnoModels adopts a one-stop service model. From experimental design, experimental operation to data analysis, the platform provides a full range of service support, effectively shortening the experimental cycle and enabling researchers to conduct GVHD research more efficiently.

3、Innovative: Utilizing advanced gene editing technology
The GVHD experimental platform of InnoModels Biotechnology makes full use of advanced gene editing technologies, such as CRISPR-Cas9, to provide new ideas and methods for GVHD research. Through precise gene editing, researchers are able to gain a deeper understanding of the pathogenesis of GVHD and thus find more effective treatments.
4. Reliable data: multi-dimensional and multi-level detection and analysis
In order to ensure the accuracy and reliability of the experimental data, the GVHD experimental platform adopts a multi-dimensional and multi-level testing and analysis method. Through strict quality control and data analysis of experimental data, the platform ensures the reliability and stability of experimental results and provides reliable data support for researchers.
In summary, the GVHD experimental platform of InnoModels Biotechnology is unique in the field of GVHD research by virtue of its features of high customization, efficiency, innovation and data reliability. By providing personalized gene modification solutions, a one-stop service model, advanced gene editing technologies, and multi-dimensional and multi-level detection and analysis methods, the platform provides comprehensive, efficient and reliable support for researchers, and promotes the continuous deepening and development of GVHD research.
In the future, the GVHD experimental platform will continue to uphold the concept of "innovation, efficiency, and reliability", and constantly explore new technologies and methods to provide more powerful support for GVHD research. At the same time, the platform will also strengthen communication and cooperation with international counterparts to jointly promote the progress of GVHD research and make greater contributions to the cause of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd